<DOC>
	<DOCNO>NCT01423110</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability BYM338 patient sporadic Inclusion Body Myositis</brief_summary>
	<brief_title>Efficacy , Safety Tolerability BYM338 Patients With Sporadic Inclusion Body Myositis</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis , Inclusion Body</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<criteria>Males Females age 4080 confirmed diagnosis sporadic Inclusion Body Myositis Unable walk least 3 meter without assistance another person Use oral beta agonist , oral corticosteroid , androgen androgen inhibitor , intravenous gamma globulin last 6 month patient history presence renal impairment and/or liver disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>sporadic Inclusion Body Myositis</keyword>
</DOC>